Trade-offs abound as big pharma makes direct-to-consumer transition
Direct-to-consumer platforms are expanding amid Trump’s pricing pressures, but uptake has hurdles.
Pricing and Market Access
Lilly first to opt for confidential reimbursement price in Germany
Pharma braces for critical French drug pricing reforms pending CEPS’s report
Navigating tariffs and diplomacy: the future of India-US pharmaceutical trade
The European Market Access Lag: 2021–2024
Trump revives plan for IRP use in US via MFN executive order
Next-generation targeting for evolving HCP engagement
Pharma faces 30-day deadline under Trump’s pricing order
